TuisEXAS • NASDAQ
add
Exact Sciences Corp
Vorige sluiting
$47,56
Dagwisseling
$46,78 - $48,92
Jaarwisseling
$40,62 - $99,56
Markkapitalisasie
8,64 mjd USD
Gemiddelde volume
2,82 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 637,52 m | 5,82% |
Bedryfskoste | 563,80 m | 6,07% |
Netto inkomste | -110,23 m | -48,65% |
Netto winsgrens | -17,29 | -40,45% |
Wins per aandeel | -0,54 | -51,85% |
EBITDA | -42,43 m | -17,16% |
Effektiewe belastingkoers | -1,67% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 652,09 m | -6,66% |
Totale bates | 6,38 mjd | 1,14% |
Totale aanspreeklikheid | 3,24 mjd | -0,09% |
Totale ekwiteit | 3,13 mjd | — |
Uitstaande aandele | 184,53 m | — |
Prys om te bespreek | 2,79 | — |
Opbrengs op bates | -3,75% | — |
Opbrengs op kapitaal | -4,22% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -110,23 m | -48,65% |
Kontant van bedrywe | -82,31 m | -115,39% |
Kontant van beleggings | -171,44 m | -306,70% |
Kontant van finansiering | -3,00 m | -102,25% |
Netto kontantverandering | -257,89 m | -244,18% |
Beskikbare kontantvloei | -118,20 m | -52,20% |
Meer oor
Exact Sciences Corp. is a molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer. Wikipedia
HUB
Gestig
01 Jan. 1995
Hoofkwartier
Webwerf
Werknemers
6 550
